Béraud et al. Platoshyn, O., Yuan, J. X., and Masliah, E. (2008a). Mechanisms of hybrid oli- gomer formation in the pathogenesis of combined Alzheimer’s and Parkinson’s diseases. PLoS ONE 3, e3135. doi: 10.1371/journal.pone.0003135 Tsigelny, I. F., Sharikov, Y., Miller, M. A., and Masliah, E. (2008b). Mechanism of alpha-synuclein oligomerization and membrane interaction: theoreti- cal approach to unstructured proteins studies. Nanomedicine 4, 350–357. Uversky, V. N. (2010). Mysterious oli- gomerization of the amyloidogenic proteins. FEBS J. 277, 2940–2953. Uversky, V. N., and Eliezer, D. (2009). Biophysics of Parkinson’s disease: structure and aggregation of alpha- synuclein. Curr. Protein Pept. Sci. 10, 483–499. Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, M., and Przedborski,S.(2000).Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.J.Neurochem.74,721–729. Volles, M. J., and Lansbury, P. T. Jr. (2002). Vesicle permeabilization by protofi- brillar alpha-synuclein is sensitive to Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595–4602. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., and Lansbury, P. T. Jr. (2001). Vesicle permeabilization by protofi- brillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson’s disease. Biochemistry 40, 7812–7819. Waetzig, V., Czeloth, K., Hidding, U., Mielke, K., Kanzow, M., Brecht, S., Goetz, M., Lucius, R., Herdegen, T., and Hanisch, U. K. (2005). c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of micro- glia. Glia 50, 235–246. Wu, X. F., Block, M. L., Zhang, W., Qin, L., Wilson, B., Zhang, W. Q., Veronesi, B., and Hong, J. S. (2005). The role of microglia in paraquat-induced dopa- minergic neurotoxicity. Antioxid. Redox Signal. 7, 654–661. Xilouri, M.,Vogiatzi, T.,Vekrellis, K., Park, D., and Stefanis, L. (2009). Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515. doi: 10.1371/journal. pone.0005515 Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L.,Wilson, B., Zhou, Y., Hong, J. S., and Zhang, J. (2005). Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 19, 533–542. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any com- α-Synuclein and TLRs mercial or financial relationships that could be construed as a potential conflict of interest. Received: 04 March 2011; accepted: 06 June 2011; published online: 29 June 2011. Citation: Béraud D, Twomey M, Bloom B, Mittereder A,TonV, Neitzke K, Chasovskikh S, Mhyre TR and Maguire-Zeiss KA (2011) α-Synuclein alters toll-like receptor expres- sion. Front. Neurosci. 5:80. doi: 10.3389/ fnins.2011.00080 This article was submitted to Frontiers in Neurodegeneration, a specialty of Frontiers in Neuroscience. Copyright © 2011 Béraud, Twomey, Bloom, Mittereder, Ton, Neitzke, Chasovskikh, Mhyre and Maguire-Zeiss. This is an open- access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with. www.frontiersin.org June 2011 | Volume 5 | Article 80 | 11